cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
12 own
19 watching
Current Price
$1.78
$-0.11
(-5.82%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
27.05M
52-Week High
52-Week High
9.45000
52-Week Low
52-Week Low
1.68000
Average Volume
Average Volume
0.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization27.05M
icon52-Week High9.45000
icon52-Week Low1.68000
iconAverage Volume0.09M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
10 months ago
Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and warrantsAdditional reduction-in-force by approximately 44% as it continues to explore strategic ...
PR Newswire
1 year ago
Thinking about buying stock in Molecular Templates, Silvergate Capital, Barnes & Noble Education, Coinbase Global, or Rivian Automotive? Thinking about buying stock in Molecular Templates, Silvergate Capital, Barnes & Noble Education, Coinbase Global, or Rivian Automotive? PR...
Globe Newswire
1 year ago
AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel ...
Globe Newswire
1 year ago
AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced ...
Globe Newswire
1 year ago
Presentations on the MT-6402 (PD-L1) and MT-5111(HER2) Phase I dose escalation programs demonstrate unique biology, continued tolerability, and dose-dependent pharmacodynamic effectsAUSTIN, Texas, June 06, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, Molecular Templates or MTEM...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.78
$-0.11
(-5.82%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00